Heron Therapeutics Revenue, Profits - HRTX Quarterly Income Statement

Add to My Stocks
$34.2 $0.4 (1.18%) HRTX stock closing price Sep 18, 2018 (Closing)

Stock analysis based on fundamentals means looking at financial statements in addition to the Heron Therapeutics stock price. An income statement is one of the three key financial statements furnished by a company, the other two being the balance sheet and the cashflow statement. The income statement is generated for a specific period of time, typically a year or a quarter. The revenue increase to $17.28M for 2018 Q2 impacts the HRTX stock. Investors typically check year over year or quarter over quarter revenue growth. The Heron Therapeutics profit and loss statement for 2018 Q2 shows a net profit of $-38.67M. Profits for last year was $-52.27M. Apart from this an investor should also check Heron Therapeutics assets and Heron Therapeutics free cash flow.

View and download details of revenue and profits for Heron Therapeutics for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q1
Heron Therapeutics Revenues or Net Sales
17.28M11.57M10.05M8.57M8.51M3.63M1.28M---
Cost Of Goods Sold (COGS)5.23M3.13M1.34M1.05M1.01M1.18M----
Heron Therapeutics Gross Profit
12.05M8.43M8.72M7.52M7.49M2.44M1.24M---
Research & Development Expense30.16M39.56M47.77M28.84M28.59M33.38M29.51M30.24M27.28M16.09M
Selling General & Admin Expense20.74M20.86M22.85M19.99M20.95M18.36M18.54M17.49M15.78M17.22M
Income Before Depreciation Depletion Amortization-38.85M-51.99M-61.9M-41.31M-42.05M-49.29M-46.81M-47.73M-43.06M-33.31M
Depreciation Depletion Amortization----------
Non Operating Income--1.01M---1.2M-0.77M--
Interest Expense--1.61M--1.03M2.37M---
Heron Therapeutics Pretax Income
-38.67M-52.26M-62.51M-41.86M-42.79M-50.32M-47.98M-48.5M-43.22M-33.44M
Provision for Income Taxes----------
MinorityInterest----------
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-38.67M-52.27M-62.49M-41.87M-42.8M-50.33M-47.96M-48.51M-43.23M-33.45M
Extraordinary Items & Discontinued Operations----------
Heron Therapeutics Profit/ Loss (Net Income)
-38.67M-52.27M-62.49M-41.87M-42.8M-50.33M-47.96M-48.51M-43.23M-33.45M
Average Shares used to compute Diluted EPS71.95M64.72M57.59M54.18M53.79M50.53M39.28M39.11M37.05M36.23M
Average Shares used to compute Basic EPS71.95M64.72M57.59M54.18M53.79M50.53M39.28M39.11M37.05M36.23M
Income Before Nonrecurring Items-38.67M-52.27M-62.49M-41.87M-42.8M-50.33M-47.96M-48.51M-43.23M-33.45M
Income from Nonrecurring Items----------
Heron Therapeutics Earnings Per Share Basic Net
-0.54-0.81-1.09-0.77-0.80-1.00-1.22-1.24-1.17-0.92
Heron Therapeutics Earnings Per Share Diluted Net
-0.54-0.81-1.09-0.77-0.80-1.00-1.22-1.24-1.17-0.92
EPS Diluted Before Nonrecurring Items-0.54-0.81-1.09-0.77-0.80-1.00-1.22-1.24-1.17-0.92
Preferred Dividends Acc Pd----------
Dividends Common0.000.000.00-------
Dividend Per Share Common0.000.000.000.000.000.000.000.000.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

The key things to look for in an income statement while doing Heron Therapeutics stock analysis are:

  • Revenue: This is the inflow that is generated from the sale of goods or services and is $17.28M for this quarter of 2018 Q2. Our Heron Therapeutics revenue chart gives a clear visual representation of how the topline or sales growth has been. Investors often invest only in those companies where the revenue is growing at a steady rate.
  • Bottom line: Most businesses like Heron Therapeutics try to grow their profits by growing their topline and by increasing their operating efficiency. A healthy bottom line growth implies a good investment.

The income statement is also called the profit and loss statement. Apart from the HRTX income statement, one can check the Heron Therapeutics historical stock prices to check how the price has moved with time.

Heron Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
51.84
Dividend Yield
0%